Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $383.48M | $314.71M | $282.86M | $294.01M | $224.96M | $236.98M | $181.28M | $159.25M |
| Cost of Revenue | $94.03M | $75.58M | $68.98M | $66.63M | $91.72M | $38.59M | $25.07M | $21.05M |
| Gross Profit | $289.45M | $239.14M | $213.88M | $227.38M | $133.24M | $198.40M | $156.20M | $138.20M |
| Gross Margin | 75.48% | 75.99% | 75.61% | 77.34% | 59.23% | 83.72% | 86.17% | 86.78% |
| Operating Expenses | $411.82M | $367.84M | $296.20M | $260.26M | $256.79M | $248.69M | $169.21M | $140.49M |
| Operating Income | $-122.37M | $-128.70M | $-82.31M | $-32.87M | $-123.55M | $-50.29M | $-13.00M | $-2.28M |
| Operating Margin | -31.91% | -40.89% | -29.10% | -11.18% | -54.92% | -21.22% | -7.17% | -1.43% |
| Net Income | $-146.37M | $-134.66M | $-99.19M | $-49.59M | $-120.35M | $15.42M | $-12.95M | $-92.00K |
| Net Margin | -38.17% | -42.79% | -35.07% | -16.87% | -53.50% | 6.51% | -7.14% | -0.06% |
| EPS (Basic) | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.41 | $-0.37 | $-0.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |